Sominex

Sominex is a trademark applied to different products in different countries rather than a single globally standardized medicine. Its best-known uses have been as an over-the-counter sleep-aid brand in the United States and the United Kingdom. The U.S. product has historically undergone several formula changes and is currently associated with diphenhydramine hydrochloride, a sedating first-generation antihistamine. The UK product has traditionally used promethazine hydrochloride, another first-generation antihistamine with sedative properties. Because the active ingredients, manufacturers, labeling, regulatory status, and commercial owners differ by market, a reference to Sominex does not necessarily identify the same medicine everywhere. The brand was promoted extensively in the United States from at least the 1950s, including television and newspaper advertising. Early campaigns presented Sominex as a reliable remedy for sleeplessness and sometimes used hospital-testing or medical-authority language. During the 1960s and 1970s, U.S. formulations included combinations involving scopolamine derivatives, methapyrilene, salicylamide, and other ingredients. These products became part of wider regulatory scrutiny of nonprescription sleep aids after evidence and expert testimony raised questions about efficacy, toxicity, labeling, and possible carcinogenicity. Methapyrilene-containing products were particularly controversial after animal testing associated the substance with liver tumors under experimental conditions. The FDA and U.S. health officials subsequently pressed manufacturers to remove or reformulate products containing ingredients considered unsafe or inadequately supported. Sominex 2, introduced by the J. B. Williams Company in 1975, generated a separate regulatory dispute. Authorities objected to warnings, child-resistant packaging, and the legality of diphenhydramine's use in an over-the-counter sleep product at that time. California officials sought to halt sales, and the FDA ordered outstanding Sominex 2 stock removed from the market. Later U.S. formulations moved toward diphenhydramine, and the FDA approved diphenhydramine hydrochloride and citrate for relevant uses in 1989. The modern U.S. brand is marketed by Prestige Brands, sometimes through Medtech Products, and some products have also been repackaged under the Handy Solutions label by Navajo Manufacturing Co. Ownership of the U.S. trademark changed during the consumer-health-brand consolidation of the early 2010s. GlaxoSmithKline announced plans to divest Sominex in 2011, and Prestige acquired it with a larger group of brands later that year. The brand therefore operates more as a licensed or market-specific consumer-health asset than as an independently listed company. In the UK, Sominex has been sold as an over-the-counter hypnotic containing promethazine hydrochloride since at least the 1980s. Actavis marketed both the conventional product and Sominex Herbal, which used hops, valerian, and passionflower extracts. Actavis launched its first UK television campaign for Sominex in 2010 in an effort to compete with larger consumer-health players. The product was reportedly withdrawn in 2018, while Teva UK Limited was identified as the marketer in 2024. In India, Lunar BioPharma uses the Sominex name for a gastrointestinal nutritional supplement unrelated to the U.S. and UK sleep-aid formulations. Sominex's positioning has consequently shifted from a heavily advertised mass-market sleeping remedy to a regulated, short-term self-care product whose use is constrained by warnings about sedation, impairment, interactions, and inappropriate long-term or recreational use. Medical and sleep organizations have questioned the evidence supporting routine use of over-the-counter antihistamines for insomnia. The brand remains active in at least some markets, but its identity and formulation must be interpreted by country and package labeling.

Sominex emerged in the United States as a heavily advertised nonprescription sleep-aid name during the 1950s. Television commercials used memorable visual and musical devices, including a bouncing tablet motif, while newspaper advertising described the product as hospital-tested. By the late 1950s and early 1960s, the brand was part of congressional and regulatory discussions about exaggerated claims and the marketing of patent medicines. The U.S. formulation changed repeatedly. Products sold in the early 1970s used combinations that included scopolamine-related compounds, methapyrilene, and salicylamide. Investigators and clinicians reported concerns about anticholinergic toxicity, hallucinations, disorientation, and limited effectiveness. Research into methapyrilene raised additional concern after experimental animal findings, prompting FDA action and requests from federal health officials to remove or reformulate products containing the ingredient. By 1979, manufacturers were shifting away from several older ingredients, including methapyrilene and certain bromides, while Sominex was being marketed with alternative antihistamines. The formula later moved toward diphenhydramine, which became the active ingredient associated with the modern U.S. product. Sominex 2 was introduced by J. B. Williams in July 1975. California authorities challenged the product's warnings for pregnant or nursing users and people with respiratory disease, as well as the lack of an alcohol warning. The FDA also objected to child-resistant packaging and labeling. The resulting order and recall made Sominex 2 an important example of the regulatory transition affecting older over-the-counter sleep medicines. In Britain, Sominex developed along a different path. Actavis marketed a promethazine hydrochloride hypnotic under the name from at least 1985 and also sold Sominex Herbal, based on hops, valerian, and passionflower. A television campaign in 2010 sought to strengthen the brand against competitors. Actavis later withdrew the product in 2018, while Teva UK Limited was identified as the UK marketer in 2024. Corporate ownership in the United States shifted from GlaxoSmithKline to Prestige Brands in 2011. The transaction reflected a wider pattern in which large healthcare companies sold mature consumer brands to companies focused on over-the-counter products. In other markets, the trademark has had separate commercial histories. Canada has references to diphenhydramine and professional counseling material mentioning Sominex, while Lunar BioPharma in India uses the name for a gastrointestinal nutritional supplement unrelated to the principal sleep-aid products. Modern discussion of Sominex focuses less on advertising than on safe use. Diphenhydramine and promethazine can cause sedation, impaired attention, blurred vision, anticholinergic effects, and other adverse reactions. Long-term use, excessive dosing, interactions, and misuse have prompted continuing concern. The American Academy of Sleep Medicine cited Sominex among over-the-counter sleep aids for which evidence was insufficient to support a recommendation for routine insomnia treatment.

1. 2024Teva identified as UK marketer

   Teva UK Limited was identified as marketing the UK medicine.

   Source
2. 2018Actavis withdraws UK Sominex

   The UK promethazine product was reported withdrawn by Actavis.

   Source
3. 2011Prestige Brands becomes U.S. owner

   Prestige acquired Sominex from GlaxoSmithKline in a larger portfolio transaction.

   Source
4. 1989FDA approves diphenhydramine salts for relevant use

   The FDA approved diphenhydramine hydrochloride and citrate, supporting the later U.S. formulation direction.

   Source
5. 1985UK promethazine product documented

   Sominex was available in the UK as an over-the-counter promethazine hypnotic by at least this period.

   Source
6. 1979U.S. formulas begin moving away from older ingredients

   Regulatory pressure over methapyrilene and other ingredients led manufacturers to reformulate nonprescription sleep aids.

   Source
7. 1975Sominex 2 introduced and recalled

   J. B. Williams launched Sominex 2; California and federal authorities subsequently challenged its warnings, packaging, and regulatory status, leading to removal of outstanding stock.

   Source
8. 1950U.S. television promotion documented

   Sominex was being promoted through television advertising by the 1950s.

   Source

Market-specific, short-term over-the-counter relief for occasional sleeplessness; the same trademark is also used for an unrelated Indian gastrointestinal supplement.

• U.S. SominexOTC sleep aid

  The contemporary U.S. product is associated with diphenhydramine hydrochloride, a sedating first-generation antihistamine. It is intended for short-term relief of occasional sleeplessness, with warnings relating to drowsiness, impaired performance, interactions, and inappropriate use. The product has also appeared under different packaging and distribution arrangements, including Medtech Products and Handy Solutions repackaging.

• Sominex 2OTC sleep aid1975

  Introduced by J. B. Williams in 1975, Sominex 2 became the subject of a California enforcement action and an FDA removal order. Authorities cited missing or inadequate warnings, non-child-resistant packaging, and regulatory concerns involving diphenhydramine. Historical advertising later associated the product with diphenhydramine efficacy and physician-preference claims.

• UK SominexOTC hypnotic

  The UK version has used promethazine hydrochloride, a first-generation antihistamine with sedative properties. It was sold as an over-the-counter sleep medicine from at least the 1980s, although availability and marketer changed over time. Teva UK Limited was identified as the marketer in 2024.

• Sominex HerbalHerbal sleep aid

  A UK product marketed by Actavis using hops, valerian, and passionflower extracts as its natural active ingredients. It represented an herbal extension of the Sominex sleep-aid range rather than a formulation based on promethazine or diphenhydramine.

• Indian Sominex supplementNutritional supplement

  Lunar BioPharma Pvt. Ltd. uses the Sominex name in India for a nutritional supplement positioned for gastrointestinal relief. This product is unrelated to the principal U.S. and UK sleep-aid formulations.

• 2010Actavis UK television campaign

  United Kingdom

  Actavis ran its first reported television campaign for Sominex in the UK to compete with larger brands and improve the market position of its promethazine product.

  Outcome. The campaign marked a renewed promotional effort before Actavis later withdrew the product from the UK market.

  Source
• 1958Sominex television tablet campaign

  United States

  A U.S. commercial used the image of a sleeping-pill tablet as a bouncing-ball device accompanying a jingle. The spot was shown on an episode of Arthur Murray Party.

  Outcome. The campaign illustrates the brand's early mass-media positioning as a memorable consumer sleep remedy.

  Source

• 2011Transfer the U.S. brand to Prestige BrandsM&A

  GlaxoSmithKline announced a plan to divest Sominex as part of a broader portfolio strategy.

  What changed. Prestige Brands acquired Sominex and 16 other brand names in December 2011.

  Aftermath. Sominex became part of Prestige's consumer-health portfolio in the United States.

  Transaction value. US$661.6 million (December 2011; transaction covering Sominex and 16 other brand names)

  Source
• 1979Reformulate U.S. sleep-aid productsGeneration change

  Federal scrutiny questioned the safety and effectiveness of methapyrilene and several other ingredients used in older sleep-aid products.

  What changed. Manufacturers, including the Sominex producer, shifted formulations away from methapyrilene and other disputed ingredients; later U.S. versions used diphenhydramine.

  Aftermath. The change aligned Sominex with the emerging regulatory framework for antihistamine-based OTC sleep aids.

  Source

• 1979Methapyrilene safety controversyControversy

  Older U.S. Sominex formulations contained methapyrilene. After preliminary animal research associated high-dose exposure with liver tumors, federal officials urged removal or reformulation of affected over-the-counter products, including Sominex.

  Source
• 1975Sominex 2 regulatory and labeling disputeControversy

  California officials and the FDA challenged Sominex 2 over warnings, child-resistant packaging, and the then-regulatory status of diphenhydramine in an OTC sleep aid. The FDA ordered remaining stock removed.

  Source

• 2011GlaxoSmithKline announces divestment of Sominex

  GlaxoSmithKline announced that it would divest Sominex as part of a broader consumer-health brand transaction.

  M&A
  Source
• 2011Prestige Brands acquires Sominex and other consumer brands

  Prestige Brands acquired Sominex together with 16 other brand names from GlaxoSmithKline.

  M&A
  Source
• 2010UAE recall involving promethazine Sominex

  A promethazine formulation carrying the Sominex name was included in a United Arab Emirates recall issued under Ministerial Decree No. 366 before approval.

  RecallRegulation
  Source
• 2010Actavis launches UK television campaign

  Actavis ran its first reported UK television promotion for Sominex to support competition in the sleep-aid market.

  Campaign
  Source
• 1975FDA orders Sominex 2 removed from the U.S. market

  The FDA ordered removal of Sominex 2 stock because of packaging and labeling concerns and objections to its then-current over-the-counter use of diphenhydramine.

  RecallRegulation
  Source

1. Sominex